FGAM
BBIO icon

Financial Gravity Asset Management’s BridgeBio Pharma BBIO Stock Holding History

Financial Gravity Asset Management’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-3
Closed -$91 – 1445
2024
Q1 		$91 Buy
3
+1
+50% +$34 ﹤0.01% 972
2023
Q4 		$66 Buy
+2
New +$60 ﹤0.01% 1109

Other funds holding BBIO

KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Financial Gravity Asset Management's BBIO Position: Q2 2024 in Review

Financial Gravity Asset Management sold out of BridgeBio Pharma (BBIO) in Q2 2024, closing a stake of 3 shares — an estimated $91 sold.

Financial Gravity Asset Management first reported a position in BBIO in Q4 2023 and held it in 2 quarters. The position peaked at $91 in Q1 2024. 251 funds tracked by Wall St. Rank hold BBIO as of Q2 2024.

  • Financial Gravity Asset Management reported no remaining BridgeBio Pharma position as of Q2 2024 after selling out during the quarter.
  • Financial Gravity Asset Management sold 3 BridgeBio Pharma shares in Q2 2024, an estimated $91.
  • Financial Gravity Asset Management first reported a position in BridgeBio Pharma in Q4 2023 and held it in 2 quarters.
  • Financial Gravity Asset Management's BridgeBio Pharma position peaked at $91 in Q1 2024.
  • 251 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2024.

Based on Financial Gravity Asset Management's 13F filing for Q2 2024, filed 6 Aug 2024.